ELVN — Enliven Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00Annual cashflow statement for Enliven Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -51.4 | 1.49 | -71.6 | -89 | -104 |
| Depreciation | |||||
| Non-Cash Items | 4 | -32.3 | 8.62 | 20.1 | 34.3 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 0.514 | -5.36 | 1.4 | -4.54 | -1.12 |
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Net Change in Other Assets & Liabilities | |||||
| Cash from Operating Activities | -46.8 | -35.6 | -61.3 | -73.2 | -70.3 |
| Capital Expenditures | -0.012 | -0.363 | -0.149 | -0.044 | -0.158 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -1.62 | 76.9 | -148 | -36 | -174 |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -1.63 | 76.5 | -148 | -36 | -174 |
| Financing Cash Flow Items | -0.578 | -1.23 | 234 | 0 | -0.217 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Cash from Financing Activities | 49.1 | -1.23 | 234 | 133 | 219 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 0.698 | 39.7 | 24.6 | 24 | -25.3 |